- Home
- SKYE vs WHF Comparison
SKYE vs WHF Comparison
Compare SKYE & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- WHF
- Stock Information
- Founded
- SKYE 2012
- WHF 2011
- Country
- SKYE United States
- WHF United States
- Employees
- SKYE N/A
- WHF N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- WHF Finance Companies
- Sector
- SKYE Health Care
- WHF Finance
- Exchange
- SKYE Nasdaq
- WHF Nasdaq
- Market Cap
- SKYE 73.4M
- WHF 212.0M
- IPO Year
- SKYE N/A
- WHF 2012
- Fundamental
- Price
- SKYE $4.32
- WHF $8.74
- Analyst Decision
- SKYE Buy
- WHF Sell
- Analyst Count
- SKYE 6
- WHF 4
- Target Price
- SKYE $16.60
- WHF $10.83
- AVG Volume (30 Days)
- SKYE 1.9M
- WHF 106.0K
- Earning Date
- SKYE 08-08-2025
- WHF 08-07-2025
- Dividend Yield
- SKYE N/A
- WHF 20.40%
- EPS Growth
- SKYE N/A
- WHF N/A
- EPS
- SKYE N/A
- WHF 0.39
- Revenue
- SKYE N/A
- WHF $86,143,000.00
- Revenue This Year
- SKYE N/A
- WHF N/A
- Revenue Next Year
- SKYE N/A
- WHF N/A
- P/E Ratio
- SKYE N/A
- WHF $22.24
- Revenue Growth
- SKYE N/A
- WHF N/A
- 52 Week Low
- SKYE $1.14
- WHF $8.44
- 52 Week High
- SKYE $8.26
- WHF $12.73
- Technical
- Relative Strength Index (RSI)
- SKYE 81.18
- WHF 39.48
- Support Level
- SKYE $2.12
- WHF $8.62
- Resistance Level
- SKYE $2.22
- WHF $8.88
- Average True Range (ATR)
- SKYE 0.35
- WHF 0.16
- MACD
- SKYE 0.20
- WHF -0.04
- Stochastic Oscillator
- SKYE 84.03
- WHF 11.54
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.